Skip to content

Chronic LSD administration produces changes in mPFC gene and protein expression relevant to schizophrenia, as determined by RNA‐Seq and DIGE

David Martin, David E. Nichols, Charles D. Nichols

The FASEB Journal April 1, 2012 DOI: 10.1096/fasebj.26.1_supplement.1044.6 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Animal model study Peer reviewed
Population Rats
Intervention LSD
Dose low doses
Duration Three-month treatment
Topics LSD
Keywords Prefrontal cortex Schizophrenia object-oriented programming Anhedonia Gene expression Psychosis Dopamine Genetics
Key points Chronic low-dose LSD treatment in rats induces persistent behavioral and molecular changes that mirror features of schizophrenia, supporting its use as a new animal model.

Abstract

The objective of this work is to characterize genetic and proteomic changes in a novel rat model of schizophrenia. Three‐month treatment with low doses of the hallucinogenic drug, LSD, induces a range of abnormal behaviors including social deficits, hyperactivity, and anhedonia. These behavioral changes persist in the absence of drug , and likely result from neuroadaptive changes in the medial prefrontal cortex (mPFC), an area of the brain highly implicated in schizophrenia and in the actions of LSD. DIGE proteomic analysis revealed 12 differentially expresed proteins in the mPFC of LSD‐treated rats, 9 of which have previously been identified as dysregulated in schizophrenic post‐mortem cortex. RNA was sequenced using RNA‐Seq, and bioinformatic analysis of the sequence data reveals that chronic LSD induces alterations in genes for each of the major neurotransmitter systems associated with schizophrenia, as well as other genes associated with this disease. Functional clustering of differentially expressed genes reveals subsets involved in synaptic plasticity are highly represented. This data supports the construct validity of chronic LSD as a new model of schizophrenia, and suggests that further investigation of the effects of LSD may reveal important mechanistic insight into the pathophysiology of schizophrenia, and that our model may be used as a discovery platform. Supported by NIH RO1MH092511.

Comparable studies

Other preclinical and animal studies on LSD, most cited first.

Study Year Design Participants
Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex Human embryonic kidney 293 cells stably expressing 5-HT2ARs; wild-type and 5-HT2AR... 2003 Experimental study
Evidence for a central 5‐hydroxytryptamine receptor stimulation by lysergic acid diethylamide Rats 1968 Experimental study
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression Rats 2020 Preclinical study
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Male mice 2021 Multidisciplinary experimental study with in vivo electrophysiology, optogenetics, behavioral paradigms, molecular biology, and conditional knockout mice
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Mice and cultured rat cortical neurons 2023 Preclinical study

Explore topics